Puma Biotechnology Inc. (PBYI)

13.15
0.06 0.45
NASDAQ : Health Technology
Prev Close 13.21
Open 13.28
Day Low/High 13.10 / 13.55
52 Wk Low/High 12.81 / 65.45
Volume 375.28K
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 38.61M
Market Cap 533.23M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Puma Biotechnology To Present At UBS Global Healthcare Conference

Puma Biotechnology To Present At UBS Global Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

July 1st Options Now Available For Puma Biotechnology (PBYI)

July 1st Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the July 1st expiration.

Puma Biotechnology Reports First Quarter 2016 Financial Results

Puma Biotechnology Reports First Quarter 2016 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016

Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American Association for Cancer Research (AACR) Annual...

Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology

Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in...

Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application

Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application

Puma Biotechnology (PBYI) stock is lower in early-morning trading on Tuesday after the company announced that it will delay filing its New Drug Application (NDA) for a breast cancer drug.

Puma Biotechnology Updates Timeline For Filing New Drug Application

Puma Biotechnology Updates Timeline For Filing New Drug Application

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2016.

Puma Biotechnology To Present At Cowen's Health Care Conference

Puma Biotechnology To Present At Cowen's Health Care Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Fourth Quarter And Full Year 2015 Financial Results

Puma Biotechnology Reports Fourth Quarter And Full Year 2015 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2015.

Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference

Puma Biotechnology To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Announces The Conclusion And Final Results Of Eshelman's Consent Solicitation

Puma Biotechnology Announces The Conclusion And Final Results Of Eshelman's Consent Solicitation

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the deadline for Fredric Eshelman to deliver the requisite consents expired on February 15, 2016, and that Puma's shareholders have...

Puma Biotechnology's ExteNET Phase III Study Published Online In The Lancet Oncology

Puma Biotechnology's ExteNET Phase III Study Published Online In The Lancet Oncology

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the ExteNET Phase III clinical trial of neratinib in patients with early stage HER2 positive breast cancer were published in...

Puma Biotechnology To Participate In Fireside Chat At Leerink Partners Global Healthcare Conference

Puma Biotechnology To Participate In Fireside Chat At Leerink Partners Global Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Interesting PBYI Put And Call Options For September 16th

Interesting PBYI Put And Call Options For September 16th

Investors in Puma Biotechnology, Inc. saw new options become available this week, for the September 16th expiration.

Puma Biotechnology Stock Sees Short Interest Make 46% Move

Puma Biotechnology Stock Sees Short Interest Make 46% Move

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 2,003,507 share increase in total short interest for Puma Biotechnology, Inc. , to 6,371,236, an increase of 45.87% since 12/15/2015.

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman's Consent Solicitation

Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman's Consent Solicitation

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that shareholders representing over 80% of the Company's shares outstanding have rejected the proposals initiated by Fredric Eshelman by revoking...

Puma Biotechnology To Present At J.P. Morgan Healthcare Conference

Puma Biotechnology To Present At J.P. Morgan Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

My biotech and pharma superlatives for 2015.

Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card

Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card

Puma Biotechnology, Inc. (NYSE: PBYI) ("Puma" or the "Company") announced that independent proxy advisory firm Egan-Jones Proxy Services recommends that Puma shareholders revoke all consents on the BLUE Consent Revocation...

ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card

ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation By REVOKING CONSENT On Puma's BLUE Consent Revocation Card

Puma Biotechnology, Inc. (NYSE: PBYI) ("Puma" or the "Company") today announced that ISS, the leading independent proxy advisory firm, recommends that Puma shareholders revoke all consents on the BLUE Consent Revocation...

Puma Biotechnology Expands Third Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients

Puma Biotechnology Expands Third Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has expanded the third cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors...

Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea

Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, will host a conference call and slide presentation to discuss preliminary results of its Phase II study looking at the incidence and severity of diarrhea...

8 Stocks Spiking on Unusually High Volume

8 Stocks Spiking on Unusually High Volume

These stocks rising on unusual volume are within range of triggering breakout trades.

Puma Biotechnology Presents 3-Year Disease Free Survival Data From Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) At The 2015 San Antonio Breast Cancer Symposium

Puma Biotechnology Presents 3-Year Disease Free Survival Data From Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (ExteNET Trial) At The 2015 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the presentation of updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant...

Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2015 San Antonio Breast Cancer Symposium

Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2015 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2015...

Puma Biotechnology Announces Results Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer

Puma Biotechnology Announces Results Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from a randomized Phase II clinical trial of Puma's investigational drug PB272 (neratinib) in the neoadjuvant treatment of locally...

TheStreet Quant Rating: D- (Sell)